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transferred from one point of care to the next with treatment continuation potentially 
being delayed. 88 providers of care (60 institutions), 30 patients diagnosed with 
schizophrenia and 17 patients diagnosed with depression were surveyed through in-
depth interviews. The total number of questions was 56 for providers, and 54 ques-
tions for patients. RESULTS: A total of 56% of patients diagnosed with schizophrenia 
(mean age 45 years, mean duration of illness 16 years) experience waiting times when 
transferred to an outpatient rehabilitation center, 50% while being transferred to an 
institution of assisted working or to a place of sheltered living (33%). Patients diag-
nosed with major depression (mean age 45 years; mean duration of illness 13 years) 
experience waiting times when transferred to an institution of assisted working (63%), 
to an outpatient rehabilitation center (57%) or to a psychotherapist (56%). Providers 
experience waiting times when they transfer patients to psychotherapists (55%). a 
total of 40% of patients diagnosed with schizophrenia and 58% of patients diagnosed 
with major depression perceive waiting times as heavily constraining, affecting their 
treatment and care, and potentially leading to a setback in their treatment progress. 
Providers see capacity constraints as main reason for waiting times. CONCLUSIONS: 
This study describes waiting times in coordination of mental health care between 
different providers as a problem. Potential negative effects on treatment success show 
the need for optimization. 
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OBJECTIVES: The Alcohol Dependence Scale (ADS) is a quantitative measure of the 
severity of alcohol dependence consistent with the concept of the alcohol dependence 
syndrome. The 25 items cover alcohol withdrawal symptoms, impaired control over 
drinking, awareness of a compulsion to drink, increased tolerance to alcohol, and 
salience of drink-seeking behavior. This study aims to adapt the ADS questionnaire 
into Turkish culture and check the reliability and validity of the questionnaire cultur-
ally. METHODS: The original instrument was translated and back translated by two 
independent translators. For psychometric measures, a small sample was used to check 
the initial comprehension and factibility. Cronbach’s Alfa was used to assess reliability 
and factor analysis to assess dimensionality. The EuroQol questionnaire and corre-
sponding Visual Analogue Scales were used for concurrent validity. RESULTS: A total 
of 200 students between the ages of 19–28 were participated in the study. Mean age 
was 22. The internal consistency coefﬁ cient (Cronbach’s alpha) of ADS was 0.92. 
Factor analysis of the scale revealed that it was composed of six factors with Eigen-
values >1.0, accounting for 74 % of the total variance. Correlations were moderate 
with EuroQol and VAS. CONCLUSIONS: The culturally adapted Alcohol Depen-
dence Scale has good validity and reliability. The instrument is likely to be suitable 
for the evaluation of alcohol dependence of people in Turkey.
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OBJECTIVES: In health economics, cost-effectiveness analyses are performed based 
on standardized established methods expressing outcomes in terms of costs per qual-
ity-adjusted life-year (QALY). In the ﬁ eld of care for criminal youth, interventions are 
increasingly drawn into the medical domain and towards reimbursement protocols so 
that a common cost-effectiveness measure becomes a necessity. However, cost-effec-
tiveness of these interventions has so far not been expressed in terms of cost per QALY, 
but in terms of clinical measures. The aim of this study is to explore the applicability 
of the QALY as effect measure of interventions for criminal youth. METHODS: The 
112 juvenile delinquents between 12 and 18 years included in this study were recruited 
at the start of Functional Family Therapy (FFT) from ﬁ ve mental health institutions 
in The Netherlands. Treatment efﬁ cacy was assessed using clinical outcome measures 
SDQ, YSR, CBCL, and PACS. Quality of life was measured using EuroQol EQ-5D. 
Data was analyzed to determine whether quality of life and clinical outcome measures 
show a signiﬁ cant correlation. Dutch population EQ-5D data was consulted to deter-
mine whether EQ-5D sufﬁ ciently captures differences between criminal and non-
criminal groups. RESULTS: Comparison between groups of criminal and non-criminal 
youths yielded no signiﬁ cant differences for juvenile delinquents or their parents. 
Correlation between several clinical outcome measures and EQ-5D scores of delin-
quent youths has been found suggesting that EQ-5D captures some differences in 
criminal behaviour. CONCLUSIONS: The study conﬁ rms the expected correlation 
between several classical forensic effect measures and general health economics out-
comes, but several aspects were not reﬂ ected by the QALY. Furthermore, the QALY 
measure insufﬁ ciently distinguishes between criminal and non criminal groups. We 
suggest further research before considering the application of the QALY as an effect 
measure for delinquent youths.
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BACKGROUND: High placebo response is observed in trials measuring subjective 
outcomes as in the case of GAD. This contributes to investigational drug failure owing 
to lack of differentiation between intervention and control group. Placebo run-in is 
frequently used to eliminate early responders however this has been criticised on the 
ground that it favours the active treatment. OBJECTIVES: To test the hypothesis that 
“The use of placebo run-in overestimates the treatment effect in placebo-controlled 
trials conducted in GAD”. METHODS: The Medline and EMBASE databases were 
searched to retrieve randomised, placebo-controlled trials conducted in adult GAD 
patients. Citations were screened on the basis of title and abstract and full text article 
of citations meeting eligibility criteria were sourced for detailed evaluation. Following 
this, citations reporting relevant outcomes were extracted using a pre-deﬁ ned extrac-
tion grid. Clinically relevant dichotomous outcomes: CGI-Improvement response, 
HAM-A response, and HAM-A remission were extracted. Considering heterogeneity 
among studies included, the random effects meta-analysis was performed in STATA 
9.0 using a standard meta-analysis approach. Results are presented as odds ratios with 
a 95% conﬁ dence interval. RESULTS: The literature search retrieved 1133 citations 
of which 41 were included following detailed evaluation (23 used placebo run-in 
phase). The point estimate for the relative treatment effect was similar (conﬁ dence 
interval overlap widely) irrespective of the use of placebo run-in phase (OR: 2.13 with 
run-in vs. 2.19 without run-in). Results were similar when individual outcomes were 
analyzed separately (HAM-A response OR: 2.17 vs. 2.14; CGI-I response OR: 2.20 
vs. 2.13; HAM-A remission OR: 1.98 vs. 2.05). CONCLUSIONS: Irrespective of 
outcomes considered, there was no statistically signiﬁ cant difference in the effect size 
between trials involving placebo run-in phase compared to those that did not. Our 
results do not support the hypothesis that the inclusion of placebo run-in overestimates 
the relative treatment effect in GAD. 
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OBJECTIVES: The study aimed to develop a standardized scale for co-morbidity 
assessment in Chronic Lymphocytic Leukaemia (CLL) patients to support physicians 
for selecting the optimal treatment according to the patient co-morbidity proﬁ le. 
METHODS: The co-morbidity scale was developed in four steps: a literature review 
to assess the existence of other scales and deﬁ ne the scale content; consensus meetings 
with ﬁ ve CLL experts to determine the content, format and weighting factor for each 
co-morbidity; a pilot study of 10 CLL patients to assess the scale feasibility; a meeting 
to agree the ﬁ nal version RESULTS: The literature review did not identify any existing 
scale but six papers related to assessment of CLL co-morbidities were selected. These 
allowed the initial selection of 21 diseases. In the expert meeting, the scale was reduced 
to 13 co-morbidities, with major impact on CLL treatment selection. Some additional 
variables (age, patient dependence and ECOG performance status) were added. Sub-
sequently, the ﬁ nal list of co-morbidities. variables and response options were agreed. 
The experts applied a weight factor to each co-morbidity, from 1 (minimal impor-
tance) to 3 (very important). a pilot study of 10 patients, using an electronic version 
of the scale, resulted in some changes but conﬁ rmed the scale’s feasibility. The ﬁ nal 
scale includes three sections. Part 1, the Functional Vital Scale, and a global assessment 
of the patient (not included in the global score). Part 2, the Co-morbidity scale, includ-
ing 11 co-morbidities weighted from 0 to 2 and scored from 0 (absence) to 2 (severe 
co-morbidity). Part 3, CLL alerts, is descriptive and includes the presence of splenec-
tomy and hypogammaglobulinemia. CONCLUSIONS: The co-morbidity scale is a 
tool to support the clinician in the selection of the optimal treatment for CLL patients. 
Further research is required to validate the scale and assess its beneﬁ ts.
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OBJECTIVES: Biologic treatment for severe forms of psoriasis proved to be effective 
and safety treatment in clinical trials. However, these drugs comprise a great ﬁ nancial 
burden. Therefore, we examined etanercept for treatment of severe forms of psoriasis 
in real clinical practice. METHODS: This was a prospective cohort non-interventional 
study of phase IV in real clinical practice which included 149 patients enrolled for 6 
months. Patients’ data were collected via electronic questionnaire. Clinical data (PASI 
score and BSA index), direct cost (inpatient and outpatient care, diagnostics, joint 
replacement etc.) and on QoL (expressed with EQ-5D and DLQI) were collected by 
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dermatologists. Results were evaluated in months 0, 3 and 6 of etanercept treatment. 
RESULTS: Average patients’ age was 46.74 years (21–75 years), average time from 
diagnosis was 24.5 years. Occurrence of psoriatic arthritis was 31.7%. 14.6% of 
patients were work disabled and 16.3% reported incapacity to work with average 
duration of 44.3 days in previous 6 months. Previous biologic treatment: 46.6% of 
patients were naive, 16.8% were after previous failure and 36.5% were after success-
fully ﬁ nished treatment with biologics within 6 previous months. Within the observa-
tion in 0, 3 and 6 months BSA index decreased from 27.12 to 18.64 to 11.47% and 
PASI score from 13.69 to 8.09 to 4.97. Utility measured according to EQ-5D increased 
from 0.7674 to 0.8344 and 0.859 and DLQI index decreased from 10.74 to 6.33 and 
4.24 in months 0, 3 and 6. Percentage of patients required inpatient care decreased 
from 25.8 to 5.0 to 0.66%, additionally average length of stay had shortened from 
15.9 to 11 days. CONCLUSIONS: Signiﬁ cant clinical effect was observed within 3 
and 6 months of etanercept treatment. QoL was increased in vast majority of patients. 
Treatment with etanercept decreased other costs associated with psoriasis—inpatient 
care (frequency and length).
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OBJECTIVES: To evaluate the cost/effectiveness of ziconotide for the spinal neuro-
modulation of cancer pain in real clinical practice, from the third payer point of view. 
METHODS: Clinical and resources consumption data related to intrathecal neuro-
modulation for severe complex pain in progressing cancer patients followed by one 
Italian centre were collected. The observation spanned from implantation to exitus or 
drop-out. Change in Numeric Rating Scale Pain Intensity (NRSPI) is the primary 
outcome of the analysis and the base of the evaluation of number of days with con-
trolled pain (at least 30% reduction). Secondary outcome measures are Karnofsky 
index, Pain Management Index, Edmonton Symptom Assessment Scale score and 
Bowel Function Index. Collected consumption data include drugs, visits, port main-
tenance, and pump recharge and amortization. Current Italian prices, real practice 
acquisition and remuneration costs are applied. RESULTS: Between January 2006 and 
August 2009, 19 patients received intrathecal ziconotide (N: 8) or morphine (N: 11). 
Both groups showed a statistically signiﬁ cant reduction in NRSPI score after 1 week 
(Z:−33,9% vs. M:−10,6%), 2 weeks (Z:−47,9% vs. M:−22,1%), and 3 weeks (Z:−
52,1% vs. M:−26,1%) from implantation, with markedly higher reductions in 
ziconotide patients, although the difference was statistically signiﬁ cant only for the 
ﬁ rst time point. Patients receiving ziconotide lived signiﬁ cantly more days with con-
trolled pain (74% vs. 40%; P < 0,05). Secondary endpoints showed similar trends. 
Average weekly cost is about c240 for ziconotide and c120 for morphine; the main 
cost driver is pharmaceutical cost (respectively 82% and 65% of the total). Higher 
ziconotide acquisition costs are partially offset by minor expenses for adjuvant thera-
pies. The incremental cost for one further day with controlled pain resulted of c50. 
CONCLUSIONS: Ziconotide permits effective treatment of extremely difﬁ cult-to-
manage pain, with improvement of the tolerability and a mild increment of cost, as 
compared to intrathecal therapy without ziconotide.
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OBJECTIVES: To systematically review the efﬁ cacy of biologics for nail psoriasis in 
plaque psoriasis and psoriatic arthritis. METHODS: MEDLINE and EMBASE were 
searched using predeﬁ ned terms: “psoriasis”, “psoriatic arthritis”, “parapsoriasis”, 
“psoriasis vulgaris”, “inﬂ iximab”, “adalimumab”, “alefacept”, “etanercept”, “goli-
mumab”, and “ustekinumab”. Abstracts from ISPOR, AAD, BAD, EADV, WCD, and 
EULAR from 2006 to 2009 were reviewed. Studies reporting both comparative and 
non-comparative ﬁ ndings from at least one biologic of interest were included if they 
reported the nail psoriasis severity index score (NAPSI), resolution, or remission. 
RESULTS: Thirteen studies were included. Golimumab and inﬂ iximab were assessed 
in randomized controlled trials (RCTs). In a RCT of inﬂ iximab, the % reduction 
(indicating improvement) from baseline NAPSI was signiﬁ cantly greater with inﬂ ix-
imab than with placebo at weeks 10 and 24, with the reduction maintained at 50 
weeks. a similar response through 24 weeks was observed in a RCT of golimumab, 
in which reductions from baseline NAPSI increased over time, from 14 to 24 weeks. 
The third comparative study evaluated adalimumab, etanercept, and inﬂ iximab in an 
observational study, favoring inﬂ iximab. The remaining studies reported ﬁ ndings for 
single-arms and examined inﬂ iximab (3 studies), alefacept (3 studies), adalimumab (3 
studies), and etanercept (1 study). At follow-up periods ranging from 12 to 72 weeks, 
these studies reported modest reductions in NAPSI scores for inﬂ iximab, etanercept, 
alefacept, and adalimumab. CONCLUSIONS: Comparative studies demonstrated that 
golimumab and inﬂ iximab appeared to be effective treatment options for nail psoria-
sis. Inﬂ iximab also has evidence supporting long-term efﬁ cacy at 50 weeks. Evidence 
from non-comparative studies supported the ﬁ ndings of the comparative evidence and 
suggested that there may be moderate nail improvement associated with adalimumab, 
alefacept, and etanercept. No quantitative synthesis of the data could be performed, 
mainly due to the paucity of comparative evidence. Further studies are warranted to 
understand the comparative efﬁ cacy of biologic treatments for nail psoriasis.
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OBJECTIVES: CAPS is a spectrum of rare inherited autoinﬂ ammatory syndromes. It 
is an ultra-orphan disease affecting approximately 70 patients in the UK. CAPS 
patients are at increased risk of developing AA amyloidosis (AA) and subsequent 
end-stage renal failure (ESRF). This study aimed to model the impact of a new treat-
ment, canakinumab, on the progression of AA in patients with CAPS. METHODS: 
A Markov model was developed which comprised four health states: CAPS, CAPS 
with AA, CAPS with ESRF and dead. Based on the literature, 25% of CAPS patients 
are thought to develop AA over their lifetime. The risks of ESRF and death in patients 
with AA were obtained from published observational studies and life expectancy in 
CAPS patients with ESRF was based on expert opinion. Excess mortality in CAPS for 
reasons other than AA was estimated from rheumatoid arthritis, another systemic 
inﬂ ammatory disease. Treatment efﬁ cacy for canakinumab was obtained from the 
results of a pivotal clinical trial. The model was run for a typical adult patient and a 
typical paediatric patient and assumed that AA was not present at treatment initiation. 
RESULTS: Assuming a UK CAPS population of 70 patients, if canakinumab was initi-
ated at the age of 4 years, a total of 18 AA and 8 ESRF cases would be avoided, and 
patients would gain 13.7 years of life on average compared to those not treated with 
canakinumab. Assuming treatment initiation at the age of 38 years (estimated mean 
age at diagnosis), a total of 11 AA and 4 ESRF cases would be avoided and patients 
would gain 10.3 years of life on average. CONCLUSIONS: Based on a model estimat-
ing the progression of AA in CAPS, treatment with canakinumab is associated with a 
gain of 10 to 14 life-years due to a reduced incidence of AA and ESRF.
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OBJECTIVES: Icatibant, a speciﬁ c bradykinin-B2 receptor antagonist, is approved for 
symptomatic treatment of acute attacks of HAE in adults with C1-esterase-inhibitor 
deﬁ ciency. Although no treatment-related serious adverse events were reported during 
randomized clinical trials with icatibant in HAE, a study of outcomes in normal clini-
cal practice is important since bradykinin-B2 receptor antagonism is a new therapeutic 
approach. The Icatibant Outcome Survey (IOS) is an international, multicentre, pro-
spective observational study designed to provide further information on the safety and 
effectiveness of icatibant in an unselected patient population. METHODS: The study 
population is all patients receiving icatibant outside of the blinded controlled studies. 
After obtaining approval from local Institutional Review Board or Ethics Committees, 
treating physicians are invited to enrol consenting patients and to participate in the 
study. a series of survey forms are used to record baseline data relating to relevant 
medical history and demographic information at study entry; details of previous HAE 
attacks, icatibant administration and outcomes; hematological, liver function and 
plasma lipid status; and any adverse events. Routine data entry occurs electronically 
via a secure link and participating physicians are encouraged to update records for 
each patient at 6-monthly intervals. Any serious adverse events will be notiﬁ ed imme-
diately in accordance with normal pharmacovigilance practice. Data harvested from 
the database will be summarised and scrutinised by an independent Steering Commit-
tee. RESULTS: Data collection commenced in July 2009 and the ﬁ rst analysis was 
done early 2010. CONCLUSIONS: The Icatibant Outcome Survey will provide 
further prospective data on safety and outcomes of use of this novel drug for acute 
treatment of HAE attacks in a ‘real world’ setting. 
